Pediatrix Medical Group (NYSE:MD) Issues Earnings Results
by Doug Wharley · The Cerbat GemPediatrix Medical Group (NYSE:MD – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07, FiscalAI reports. The company had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The firm’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.33 EPS.
Here are the key takeaways from Pediatrix Medical Group’s conference call:
- Pediatrix reported a strong Q1 with adjusted EBITDA of $58 million driven by top-line growth and 4% pricing, and management reaffirmed the full-year adjusted EBITDA outlook of $280–$300 million.
- Pricing growth (~4%) was driven by RCM cash collections (about 25% of the quarter’s pricing lift), contract admin fees (10–20%), favorable payer mix and higher neonatology acuity, but management expects RCM-driven gains to moderate and is maintaining a flat pricing outlook for the year.
- Same-unit volumes showed modest declines (NICU days down ~1%), and although management says there is no clear multiquarter trend yet, sustained volume weakness would be a downside risk to revenue and EBITDA.
- Balance sheet and capital allocation activity remain constructive—Q1 used ~$130 million of operating cash (seasonal incentive payouts), repurchased $21 million of stock, ended the quarter with just over $200 million cash and net debt of just over $385 million (~1.3x net leverage at midpoint).
- Leadership and strategic moves emphasize quality and growth—Pediatrix hired two high-profile clinical quality leaders, launched a clinician partner equity program, and is targeting expanded telehealth and OB/MFM services to deepen hospital partnerships.
Pediatrix Medical Group Stock Performance
Pediatrix Medical Group stock traded down $1.66 during mid-day trading on Tuesday, hitting $20.75. The company had a trading volume of 750,769 shares, compared to its average volume of 775,567. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 10.70 and a beta of 0.70. Pediatrix Medical Group has a 12-month low of $11.84 and a 12-month high of $24.99. The company’s fifty day moving average is $20.96 and its 200-day moving average is $21.21. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.66.
Institutional Trading of Pediatrix Medical Group
A number of hedge funds have recently added to or reduced their stakes in the company. Global Retirement Partners LLC grew its position in Pediatrix Medical Group by 68,250.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock valued at $29,000 after buying an additional 1,365 shares during the period. Transamerica Financial Advisors LLC purchased a new stake in shares of Pediatrix Medical Group during the 4th quarter worth about $30,000. Los Angeles Capital Management LLC purchased a new stake in shares of Pediatrix Medical Group during the 4th quarter worth about $43,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Pediatrix Medical Group during the 4th quarter valued at about $71,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Pediatrix Medical Group in the 2nd quarter valued at about $83,000. 97.71% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
MD has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft set a $19.00 target price on Pediatrix Medical Group in a report on Friday, February 20th. Jefferies Financial Group restated a “buy” rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Friday, March 27th. Truist Financial raised their target price on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, April 13th. Finally, UBS Group decreased their target price on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research report on Tuesday, February 24th. Two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $21.33.
View Our Latest Stock Analysis on Pediatrix Medical Group
Pediatrix Medical Group Company Profile
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.